Targeted tx for papillary RCC require tailored approaches, as enrichment strategies based solely on histology are insufficient, & selective inhibitors offer better tolerability. In met papillary RCC, VEGF- & MET-directed tx show efficacy, w/cabozantinib being a potential standard of care #RenalC24 🚨
Reposted from
The OncoAlert Network 🚨
Day 1 of #RENALC24
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Dr.Pickering
Treatment options in metastatic papillary RCC
#KidneyCancer is diverse, with distinct entities, particularly in non-clear-cell subtypes like papillary
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Comments